Biopharma capital markets coverage highlighted continued liquidity across public and private financings through early 2026. The data set of “money raised by biopharma” tracking public, private, and other rounds underscores that the IPO rebound is not limited to a single segment. This appears alongside mentions of follow-on financing activity and PIPE support in connection with licensing moves, suggesting that dealmaking continues even as companies wait for pipeline catalysts. For biotech investors, the reported fundraising totals provide a snapshot of risk appetite and funding availability during a period of shifting valuations. The combined reporting reinforces that early-2026 capital deployment remains active across diagnostics, platform companies, and clinical-stage therapeutics.